
    
      Phase Ib primary objective (STEP 1): To determine the safety of the combination of Durvalumab
      (Anti-PD-L1) + Tremelimumab (Anti-CTLA-4) + FOLFOX

      Phase II primary objective (STEP 2): To determine the efficacy of the combination of
      Durvalumab (Anti-PD-L1) + Tremelimumab (Anti-CTLA-4) + FOLFOX in terms of progression free
      survival (PFS).

      Phase II secondary Objective: To determine efficacy of the combination of Durvalumab
      (Anti-PD-L1) + Tremelimumab (Anti-CTLA-4) + FOLFOX in terms of response to treatment and
      overall survival.
    
  